The Company's intellectual property now covers the combination, formulation, and method of use of PrimeC Patent protection extends through 2042, adding four additional years to PrimeC's IP umbrella CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the issuance of a pivotal patent by the United States Patent and Trademark Off ...

Company Overview - NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, addressing significant unmet medical needs with limited therapeutic options available [3][4] Compliance with Nasdaq - NeuroSense has regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of $1.00 or more for at least 10 consecutive business days as of September 20, 2024, thus closing the prior bid price deficiency matter [1][2] Future Developments - The CEO of NeuroSense expressed optimism about advancing their treatment PrimeC, highlighting the positive momentum following Phase 2b trial results and the anticipation of initiating the Phase 3 trial in the US while continuing discussions with potential partners [3]

CAMBRIDGE, Mass., Aug. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares and warrants in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 800,000 ordinary shares and warrants to purchase an aggregate of ...

Core Insights - NeuroSense Therapeutics has announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), indicating the potential of PrimeC as a transformative therapy for ALS, with improved survival rates by 43% and slowed disease progression by 36% [1][5] Company Overview - NeuroSense Therapeutics is a late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [11] - The company aims to address significant unmet medical needs in neurodegenerative diseases through combined therapies targeting multiple pathways [11] Study Results - The 12-month study results showed a significant decrease in ferritin levels and an increase in transferrin levels, indicating improved iron metabolism and disease mitigation [3][4] - Iron levels remained stable over the 12-month dosing period, with a mean difference of 4.536 µmol/L (95% CI [1.143, 7.929], p=0.01) compared to placebo [3] Clinical Implications - The positive changes in iron metabolism correlate with improved clinical outcomes, as patients on PrimeC exhibited better functionality and survival rates compared to those on placebo [4] - The study's findings support the advancement to Phase 3 testing of PrimeC in ALS, as highlighted by Dr. Merit Cudkowicz [5] Background on ALS - ALS is an incurable neurodegenerative disease that leads to complete paralysis and death within 2-5 years from diagnosis, with over 5,000 new cases diagnosed annually in the U.S. [6] - The disease burden in the U.S. is approximately $1 billion annually, and the number of people living with ALS is projected to grow by 24% by 2040 in the U.S. and EU [6] About PrimeC - PrimeC is NeuroSense's lead drug candidate, a novel extended-release oral formulation combining ciprofloxacin and celecoxib, designed to target mechanisms contributing to ALS progression [10] - The drug has shown efficacy in reducing functional and respiratory deterioration and has received Orphan Drug Designation from the FDA and EMA [10] About the PARADIGM Study - The PARADIGM trial is a multinational, randomized, double-blind, placebo-controlled Phase 2b study involving 68 ALS participants across Canada, Italy, and Israel [8] - In the 6-month double-blind segment, PrimeC demonstrated a 29% efficacy difference compared to placebo, with a statistically significant slowing of disease progression observed [9]

Logo:https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg SOURCE NeuroSense Previously, NeuroSense reported that PrimeC significantly slowed disease progression by 36% (p=0.009) and improved survival rates by 43% compared to placebo. The Per-Protocol analysis revealed even greater benefits, with a 40% (p=0.003) improvement in ALSFRS-R scores and a 63% increase in survival rates, representing a distinguished advancement in outcomes for a controlled 12-month ALS study. Other positive clin ...

Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term Corporate Highlights for the near term include: NeuroSense CEO Alon Ben-Noon states, "We are continuing to see additional results coming in from the PARADIGM trial and as they are being analyzed and verified, we intend to share them with shareholders. We anticipate sharing 12-month survival data, ALSFRS-R –as well as providing some additional bioma ...

Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | | Page | | --- | --- | | Report of Independent Registered Public Accounting Firm | F-2 | | Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 | | Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2023, 2022 and | F-4 | | 2021 | | | Consolidated Statements of Changes in Shareholders' Equity for the Years Ended December 31, 2023, 2022 and 2021 | F-5 | | Consolidated Statements of Cash Flows fo ...

As filed with the Securities and Exchange Commission on May 20, 2024. Registration No. 333-279324 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant's name into English) State of Israel 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standa ...

CAMBRIDGE, Mass., May 20, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will be a key presenter at the ALS Drug Development Summit in Boston, Mass. on May 22, 2024, which gathers the top drug developers in the field to present findings and collaborate toward a cure for the disease. Dr. Shiran Zimri, VP of R&D at NeuroSenseDr. Shiran Zimri, VP ...

As filed with the Securities and Exchange Commission on May 10, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeuroSense Therapeutics Ltd. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant's name into English) (State or Other Jurisdiction of Incorporation or Organization) State of Israel 2834 Not Applicable (Primary Standard Industrial Classifi ...